Gene transfer into human hematopoietic progenitor cells with an episomal vector carrying an S/MAR element

Gene Therapy

Volumn 13, Issue 1, 2006, Pages 40-51

  Papapetrou, E P ^a   Ziros, P G ^a   Micheva, I D ^a   Zoumbos, N C ^a   Athanassiadou, A ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Episomal vector; Gene transfer; Hematopoietic progenitor cells; S MARs

Indexed keywords

CD34 ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; HISTONE; MATRIX ATTACHMENT REGION BINDING PROTEIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL LINE; CELL STRAIN K 562; CELL TYPE; CONTROLLED STUDY; DEACETYLATION; EPISOME; ERYTHROLEUKEMIA CELL; FIBROBLAST; GENE SILENCING; GENE TRANSFER; GENE VECTOR; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MATRIX ATTACHMENT REGION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RODENT; TRANSGENE; UMBILICAL CORD BLOOD;

ANIMALS; ANTIGENS, CD34; CELLS, CULTURED; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; MATRIX ATTACHMENT REGIONS; MICE; PLASMIDS; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSGENES;

ANIMALIA; MURINAE; RODENTIA;

EID: 29244487057     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302593     Document Type: Article

References (48)

1. Klein C, Baum C. Gene therapy for inherited disorders of haematopoietic cells. Hematol J 2004; 5: 103-111.
2. Bordignon C, Roncarolo MG. Therapeutic applications for hematopoietic stem cell gene transfer. Nat Immunol 2002; 3: 318-321.
3. Karlsson S, Ooka A, Woods NB. Development of gene therapy for blood disorders by gene transfer into haematopoietic stem cells. Haemophilia 2002; 8: 255-260.
4. Larochelle A, Dunbar CE. Genetic manipulation of hematopoietic stem cells. Semin Hematol 2004; 41: 257-271.
5. Pannell DJ, Ellis J. Silencing of gene expression: Implications for design of retrovirus vectors. Rev Med Virol 2001; 11: 205-217.
6. Hacein-Bey-Abina S, von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
7. Baum C, von Kalle C, Staal FJ, Li Z, Fehse B, Schmidt M et al. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther 2004; 9: 5-13.
8. Lipps HJ, Bode J. Exploiting chromosomal and viral strategies: The design of safe and efficient non-viral gene transfer systems. Curr Opin Mol Ther 2001; 3: 133-141.
9. Lipps HJ, Jenke AC, Nehlsen K, Scinteie MF, Stehle IM, Bode J. Chromosome-based vectors for gene therapy. Gene 2003; 304: 23-33.
10. Van Craenenbroeck K, Vanhoenacker P, Haegeman G. Episomal vectors for gene expression in mammalian cells. Eur J Biochem 2000; 267: 5665-5678.
11. Slinskey A, Barnes D, Pipas JM. Simian virus 40 large T antigen J domain and Rb-binding motif are sufficient to block apoptosis induced by growth factor withdrawal in a neural stem cell line. J Virol 1999; 73: 6791-6799.
12. Moens U, Seternes OM, Johansen B, Rekvig OP. Mechanisms of transcriptional regulation of cellular genes by SV40 large T-and small t-antigens. Virus Genes 1997; 15: 135-154.
13. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J Exp Med 1992; 176: 157-168.
14. Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 1996; 15: 3117-3126.
15. L and RAG genes are induced and the response to IL-2 enhanced in EμEBNA-1 transgenic mouse lymphocytes. Oncogene 2002; 21: 5182-5187.
16. Piechaczek C, Fetzer C, Baiker A, Bode J, Lipps HJ. A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells. Nucl Acid Res 1999; 27: 426-428.
17. Bode J, Kohwi Y, Dickinson L, Joh T, Klehr D, Mielke C et al. Biological significance of unwinding capability of nuclear matrix-associating DNAs. Science 1992; 255: 195-197.
18. Baiker A, Maercker C, Piechaczek C, Schmidt SB, Bode J, Benham C et al. Mitotic stability of an episomal vector containing a human scaffold/ matrix-attached region is provided by association with nuclear matrix. Nat Cell Biol 2000; 2: 182-184.
19. Jenke BH, Fetzer CP, Stehle IM, Jonsson F, Fackelmayer FO, Conradt H et al. An episomally replicating vector binds to the nuclear matrix protein SAF-A in vivo. EMBO Rep 2002; 3: 349-354.
20. Jenke AC, Stehle IM, Herrmann F, Eisenberger T, Baiker A, Bode J et al. Nuclear scaffold/matrix attached region modules linked to a transcription unit are sufficient for replication and maintenance of a mammalian episome. Proc Natl Acad Sci USA 2004; 101: 11322-11327.
21. Gahmberg CG, Andersson LC. K562 - a human leukemia cell line with erythroid features. Semin Hematol 1981; 18: 72-77.
22. Antoniou M. Induction of erythroid-specific expression in murine erythroleukemia (MEL) cell lines. In: Murray EJ (ed). Methods in Molecular Biology: Gene Transfer and Expression Protocols. Humana Press: New York, 1991, pp 421-434.
23. Hirt B. Selective extraction of polyoma DNA from infected mouse cell culture. J Mol Biol 1967; 26: 365-369.
24. Chow CM, Athanassiadou A, Raguz S, Psiouri L, Harland L, Malik M et al. LCR-mediated, long-term tissue-specific gene expression within replicating episomal plasmid and cosmid vectors. Gene Therapy 2002; 9: 327-336.
25. Riggs MG, Whittaker RG, Neumann JR, Ingram VM. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 1977; 268: 462-464.
26. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990; 265: 17174-17179.
27. Stehle IM, Scinteie MF, Baiker A, Jenke AC, Lipps HJ. Exploiting a minimal system to study the epigenetic control of DNA replication: The interplay between transcription and replication. Chromosome Res 2003; 11: 413-421.
28. Toneguzzo F, Keating A. Stable expression of selectable genes introduced into human hematopoietic stem cells by electric field-mediated DNA transfer. Proc Natl Acad Sci USA 1986; 83: 3496-3499.
29. Keating A, Toneguzzo F. Gene transfer by electroporation: A model for gene therapy. Prog Clin Biol Res 1990; 333: 491-498.
30. Van Tendeloo VF, Willems R, Ponsaerts P, Lenjou M, Nijs G, Vanhove M et al. High-level transgene expression in primary human T lymphocytes and adult bone marrow CD34+ cells via electroporation-mediated gene delivery. Gene Therapy 2000; 7: 1431-1437.
31. Wu MH, Liebowitz DN, Smith SL, Williams SF, Dolan ME. Efficient expression of foreign genes in human CD34+ hematopoietic precursor cells using electroporation. Gene Therapy 2001; 8: 384-390.
32. Wu MH, Smith SL, Dolan ME. High efficiency electroporation of human umbilical cord blood CD34+ hematopoietic precursor cells. Stem Cells 2001; 19: 492-499.
33. Satoh Å, Hirai H, Inaba T, Shimazaki C, Nakagawa M, Imanishi J et al. Successful transfer of ADA gene in vitro into human peripheral blood CD34+ cells by transfecting EBV-based episomal vectors. FEBS Lett 1998; 441: 39-42.
34. Verma S, Woffendin C, Bahner I, Ranga U, Xu L, Yang ZY et al. Gene transfer into human umbilical cord blood-derived CD34+ cells by particle-mediated gene transfer. Gene Therapy 1998; 5: 692-699.
35. Bode J, Fetzer CP, Nehlsen K, Scinteie M, Hinrich B-H, Baiker A et al. The hitchhiking principle: Optimizing episomal vectors for the use in gene therapy and biotechnology. Gene Ther Mol Biol 2001; 6: 33-46.
36. Schaarschmidt D, Baltin J, Stehle IM, Lipps HJ, Knippers R. An episomal mammalian replicon: Sequence-independent binding of the origin recognition complex. EMBO J 2004; 23: 191-201.
37. Jenke AC, Scinteie MF, Stehle IM, Lipps HJ. Expression of a transgene encoded on a non-viral episomal vector is not subject to epigenetic silencing by cytokine methylation. Mol Biol Rep 2004; 31: 85-90.
38. Miller D, Adam M, Miller A. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239-4242.
39. Tisdale JF, Hanazono Y, Sellers SE, Agricola BA, Metzger ME, Donahue RE et al. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood 1998; 92: 1131-1141.
40. Larochelle A, Vormoor J, Hanenberg H, Wang JC, Bhatia M, Lapidot T et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy. Nat Med 1996; 2: 1329-1337.
41. Williams DA. Ex vivo expansion of hematopoietic stem and progenitor cells: Robbing Peter to pay Paul? Blood 1993; 81: 3169-3172.
42. Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol 2000; 18: 33-37.
43. Guo ZS, Wang LH, Eisensmith RC, Woo SL. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Therapy 1996; 3: 802-810.
44. Conese M, Auriche C, Ascenzioni F. Gene therapy progress and prospects: episomally maintained self-replicating systems. Gene Therapy 2004; 11: 1735-1741.
45. Sclimenti CR, Calos MP. Epstein-Barr virus vectors for gene expression and transfer. Curr Opin Biotechnol 1998; 9: 476-479.
46. Black J, Vos J-M. Establishment of an oriP/EBNA1-based episomal vector transcribing human genomic β-globin in cultured murine fibroblasts. Gene Therapy 2002; 9: 1447-1454.
47. Mucke S, Polack A, Pawlita M, Zehnpfennig D, Massoudi N, Bohlen H et al. Suitability of Epstein-Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells. Gene Therapy 1997; 4: 82-92.
48. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1994.